Providing optimal patient care in multiple sclerosis (MS) is dependent on both the patient and the healthcare system. One of the greatest challenges to optimal patient care is ensuring patient adherence to treatment. The two reasons given most often for treatment discontinuation are adverse effects and lack of efficacy. Adverse effects can be anticipated and managed, in part through well-established protocols, but also through industry-sponsored nursing support programs. These strategies can reduce needless discontinuations when patients experience common adverse effects. Lack of efficacy can be addressed for many patients by providing them with enough education to develop reasonable expectations for treatment and long-term prognosis. As important as early and continuous treatment are, these strategies are essential for providing optimal patient care in MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0b013e31818f3dcb | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A scoping review of interventions to optimize medication adherence in hypertension comorbidity.
Res Social Adm Pharm
January 2025
Department of Pharmacy Practice and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, University of Ghana, P. O. Box LG 43, Legon, Ghana. Electronic address:
Background: Patients with hypertension and other comorbidities have difficulties adhering to their medications which have negative impacts on clinical outcomes. Although some studies have identified strategies to improve medication adherence, a thorough analysis of these interventions will provide synthesized evidence for clinical decision-making and improved health outcomes for patients with hypertension comorbidities.
Aim: To conduct a scoping review on interventions that have been utilised to improve medication adherence in patients with hypertension and other co-morbid conditions.
Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
Enhancing precision in lacrimal sac tumor management through integration of multimodal imaging and intensity modulated proton therapy.
Med Dosim
January 2025
Department of Radiation Oncology, Peking University First Hospital, Beijing, China. Electronic address:
This study presents a patient with a PET-CT detected residual lacrimal sac tumor who was treated with intensity modulated proton therapy (IMPT) and concurrent chemotherapy. The patient a 49-year-old male diagnosed with squamous cell carcinoma of the left lacrimal sac had under-went endoscopic surgery. Postoperative PET-CT implied tumor residual in the left lacrimal sac.
View Article and Find Full Text PDFBlood pressure targets, medication considerations and special concerns in elderly hypertension III: Focus on stroke and neurodegenerative disorders.
J Formos Med Assoc
January 2025
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address:
Controlling hypertension has become an important issue in the elderly population in whom neurological comorbidities are highly prevalent. Most of the large-scale trials focusing on hypertension management in older populations have excluded patients with comorbid neurological disorders. However, this population requires special considerations, as the benefits of antihypertensive agents are mostly uncertain and there is a higher risk of adverse events.
View Article and Find Full Text PDFRisk of cardiovascular disease following degarelix versus gonadotropin-releasing hormone agonists in patients with prostate cancer: a systematic review and meta-analysis.
Urol Oncol
January 2025
Department of Rheumatology, Stanford University Medical Center, CA.
Background: Prostate cancer treatment involves hormonal therapies that may carry cardiovascular risks, particularly for long-term use. Gonadotropin-releasing hormone (GnRH) antagonists, such as degarelix, may offer advantages over agonists, but comprehensive comparative cardiovascular outcomes are not well established. This study aimed to systematically review and analyze the cardiovascular safety profiles of degarelix compared to those of traditional GnRH agonists, providing critical insights for optimizing treatment strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!